According to the company, Cleviprex, a novel intravenous antihypertensive, represents an advancement over currently available therapies, providing rapid and precise control of blood pressure in the critical care setting.
Backed by comprehensive data in the emergency department, operating room and intensive care unit, Cleviprex is said to offer physicians an important new therapeutic option for the management of blood pressure.
Clive Meanwell, CEO of The Medicines Company, said: “With the approval of Cleviprex, The Medicines Company continues to deliver on its vision of advancing innovation in the critical care setting.”